Regaine for Men Extra Strength Scalp Foam 5% w/w Cutaneous Foam is indicated for the treatment of alopecia androgenetica in men.
Arcutis Biotherapeutics announced positive topline results from the ARRECTOR Pivotal Phase III trial evaluating roflumilast foam 0.3%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents with scalp and body psoriasis.